Protocol Ledger

NCT07387198 · Phase II · RECRUITING

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Interventional Phase II clinical trial protocol NCT07387198 sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-29 Enrollment: 135 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07387198
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)135 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07387198
Protocol FieldVerified Registry Value
NCT IdentifierNCT07387198
Consolidated Lead SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment135 participants (ESTIMATED)
Registered Start Date2026-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07387198
Hospital Research SiteLocationSite Profile
Universitätsklinikum TübingenTübingen, GermanyOpen Hospital Dossier ->
Universitätsklinikum Hamburg-EppendorfHamburg, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI